Education
About Us
Working with TipRanks
Follow Us
Tivic Health Systems (TIVC)
NASDAQ:TIVC
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.32Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -13.19%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a period of significant strategic transformation for Tivic Health, with promising developments in their transition to a diversified immunotherapeutics company. The acquisition of Entolimod and advancements toward commercialization present considerable growth opportunities. However, the company faces financial challenges with declining revenue and cash reserves, balancing the positive strategic shifts.Company Guidance
In the first quarter of 2025, Tivic Health Systems reported a significant strategic transition, focusing on their evolution from a single-product company to a diversified immunotherapeutics entity. The company's revenue decreased to $70,000 from $334,000 the previous year, reflecting an 81% drop in unit sales due to a 92% reduction in advertising spend, as resources were redirected towards the Statera licensing agreement. Gross margins improved to 72% from 50%, and operating expenses remained steady at $1.6 million. Tivic reported a net loss of $1.5 million, consistent with the previous year, and had cash reserves of $669,000. They secured $8.4 million in strategic financing and a $25 million equity line of credit to support their transformation, particularly advancing the development of their newly acquired late-stage immunomodulatory drug candidate, Entolimod. Additionally, Tivic plans to enhance their vagus nerve stimulation program, with further updates expected in the coming months.Strategic Transition to Diversified Immunotherapeutics
Tivic Health has transitioned from a single product company to a diversified immunotherapeutics company, focusing on diseases related to immune system dysregulation.
Acquisition of Entolimod and Entolasta
Tivic Health secured exclusive worldwide rights to late-stage immunomodulatory drug candidate Entolimod and its derivative Entolasta, representing a significant value creation opportunity.
Increased Gross Margins
Gross margins increased from 50% to 72% due to reduced product support and fulfillment costs.
Strategic Financing and Capital Infusion
Tivic Health secured $8.4 million in tranche funding, a $25 million equity line of credit, and raised $1.7 million through an ATM program to support its strategic transformation.
FDA Fast Track and Orphan Drug Status
Entolimod received Fast Track and orphan drug status from the FDA for acute radiation syndrome (ARS), indicating potential for accelerated pathways and emergency use designations.
TIVC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TIVC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $4.32 | $4.27 | -1.16% |
Mar 21, 2025 | $3.55 | $3.41 | -3.94% |
Nov 15, 2024 | $6.24 | $4.92 | -21.15% |
Aug 14, 2024 | $5.30 | $4.93 | -6.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Tivic Health Systems (TIVC) report earnings?
Tivic Health Systems (TIVC) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Tivic Health Systems (TIVC) earnings time?
Tivic Health Systems (TIVC) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TIVC EPS forecast?
Currently, no data Available